Nascent Biotech, Inc. (NBIO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nascent Biotech, Inc. (NBIO) trades at $0.00 with AI Score 42/100 (Grade C). Nascent Biotech, Inc. Market cap: $86,109, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for NBIO: NBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NBIO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NBIO: the 1 perspectives are evenly split.
How is this calculated? →Nascent Biotech, Inc. (NBIO) Healthcare & Pipeline Overview
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based treatments for various cancers, including glioblastoma and epithelial cancers, with its lead candidate Pritumumab. The firm also advances its MultiPharm technology platform for broader therapeutic applications, positioning itself in the high-risk, high-reward biotechnology sector.
What Is the Investment Thesis for NBIO?
Nascent Biotech, Inc. presents an investment thesis centered on the clinical advancement of its lead monoclonal antibody, Pritumumab, and the broader potential of its MultiPharm technology platform. Pritumumab is in development for aggressive brain malignancies like glioblastoma and malignant astrocytoma, as well as various epithelial cancers, representing significant market opportunities given the high unmet medical need in these indications. Successful progression through clinical trials for Pritumumab would be a primary value driver, potentially validating its novel approach to targeting cancer cells expressing embryonic ectoderm development antigen-1. The MultiPharm platform, with its potential applications across cancer, diabetes, autoimmune disorders, and transplantation, offers diversified future growth avenues beyond the initial oncology focus. However, the company's extremely low market capitalization of 86K and its listing on the OTC Other tier signal substantial financial and operational risks, including potential challenges in securing future financing and limited liquidity. The high Beta of 1.76 also suggests elevated volatility. Future catalysts include positive clinical trial data readouts and any strategic moves towards a higher exchange listing, which could enhance visibility and access to capital.
Based on FMP financials and quantitative analysis
NBIO Key Highlights
- Market capitalization stands at $0.00 billion, reflecting its early-stage development and micro-cap status within the biotechnology sector.
- The company exhibits a Beta of 1.76, indicating higher volatility relative to the broader market, characteristic of clinical-stage biopharmaceutical firms.
- Nascent Biotech, Inc. does not currently pay a dividend, consistent with its focus on reinvesting capital into research and development for drug candidates.
Who Are NBIO's Competitors?
NBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NBIO's Key Strengths?
- Development of Pritumumab, a novel monoclonal antibody targeting tumors expressing embryonic ectoderm development antigen-1.
- Proprietary MultiPharm technology platform with potential for diverse therapeutic applications.
- Focus on high-unmet-need areas in oncology, such as glioblastoma.
- Clinical-stage development indicates progress beyond preclinical research.
What Are NBIO's Weaknesses?
- Extremely low market capitalization ($0.00B) signaling substantial financial and operational risks.
- Listing on the OTC Other tier, implying minimal financial and corporate governance requirements.
- Unknown disclosure status, limiting transparency and access to financial information.
- High reliance on the success of a single lead drug candidate, Pritumumab, in early clinical stages.
What Could Drive NBIO Stock Higher?
- Positive data readouts from clinical trials for Pritumumab in glioblastoma or epithelial cancers.
- Initiation of new clinical trials or expansion into additional indications for Pritumumab.
- Development milestones or preclinical data releases for the MultiPharm technology platform.
- Announcement of strategic partnerships or licensing agreements for drug candidates or the MultiPharm platform.
- Any corporate actions or announcements indicating a move towards a higher exchange listing.
What Are the Key Risks for NBIO?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failure for Pritumumab, which would significantly impact the company's prospects.
- Financial and operational risks associated with its OTC Other listing and extremely low market capitalization.
- Challenges in securing adequate future financing to fund ongoing research and development activities.
- Intense competition within the biotechnology and oncology sectors from larger, more established companies.
- Limited transparency and access to financial information due to its "Unknown" disclosure status.
What Are the Growth Opportunities for NBIO?
- **Advancement of Pritumumab for Glioblastoma and Malignant Astrocytoma**: Nascent Biotech's lead candidate, Pritumumab, is specifically targeting aggressive brain cancers such as glioblastoma and malignant astrocytoma. These indications represent a critical area of unmet medical need, with limited effective treatment options and poor patient prognoses. The global glioblastoma market alone is projected to reach significant valuations, driven by increasing incidence and the demand for novel therapies. Successful progression of Pritumumab through clinical trials, particularly demonstrating efficacy and safety, would validate the company's core asset and could unlock substantial market potential. The timeline for this opportunity is tied directly to the clinical trial phases and subsequent regulatory approval processes, which typically span several years.
- **Expansion of Pritumumab's Efficacy to Epithelial Cancers**: Beyond brain malignancies, Pritumumab is also being developed to target a broad spectrum of epithelial cancers, including those of the lung, breast, colon, brain, and pancreas. This represents a significantly larger addressable market compared to brain cancers alone. Each of these epithelial cancer types constitutes a multi-billion dollar market globally, with ongoing demand for improved therapeutic options. Demonstrating Pritumumab's effectiveness across these diverse indications would substantially broaden its commercial appeal and revenue potential. This growth opportunity would likely follow successful development in its primary indications, leveraging initial clinical data to support further trials in these additional cancer types.
- **Leveraging the MultiPharm Platform for Cancer Therapy**: Nascent Biotech's proprietary MultiPharm technology platform holds promise for applications within cancer therapy, extending beyond Pritumumab. This platform could enable the development of new antibody-based treatments or enhance existing ones, potentially targeting different cancer types or mechanisms. The global market for oncology biologics continues to expand, driven by innovation in targeted therapies. The MultiPharm platform could allow Nascent Biotech to develop a pipeline of novel cancer therapeutics, diversifying its risk and creating multiple shots on goal within the oncology space. The timeline for new drug candidates from this platform would involve preclinical development, followed by clinical trials.
- **Diversification into Diabetes and Autoimmune Disorders via MultiPharm**: The MultiPharm technology platform is not limited to oncology but also has potential applications in chronic diseases such as diabetes and various autoimmune disorders. These therapeutic areas represent enormous global markets with persistent demand for more effective and safer treatments. The global diabetes market, for instance, is valued in the hundreds of billions of dollars, as are markets for major autoimmune diseases. Expanding into these areas would significantly diversify Nascent Biotech's therapeutic portfolio and reduce its reliance on its oncology focus. This opportunity would involve extensive research and development to identify specific targets and develop drug candidates, followed by preclinical and clinical testing.
- **Application of MultiPharm in Transplantation**: Another promising avenue for the MultiPharm platform is in the field of transplantation. This area involves complex immunological challenges, such as preventing organ rejection and managing graft-versus-host disease, which currently rely on immunosuppressive regimens with significant side effects. The global market for transplant therapeutics is substantial, driven by the increasing number of organ transplants performed worldwide. Developing novel antibody-based therapies using MultiPharm could offer more targeted and effective solutions for transplant patients, potentially improving long-term outcomes and reducing complications. This represents a specialized but high-value market segment, requiring dedicated research and development efforts.
What Opportunities Does NBIO Have?
- Successful progression of Pritumumab through clinical trials for glioblastoma and epithelial cancers.
- Expansion of the MultiPharm platform into new therapeutic areas like diabetes, autoimmune disorders, and transplantation.
- Potential for strategic partnerships or licensing agreements to accelerate development and commercialization.
- Uplisting to a higher exchange (e.g., OTCQB, NASDAQ) to improve visibility and access to capital.
What Threats Does NBIO Face?
- Clinical trial failures or unexpected adverse events for Pritumumab or other candidates.
- Intense competition from larger pharmaceutical and biotechnology companies.
- Challenges in securing future financing due to low market cap and OTC Other listing.
- Regulatory hurdles and lengthy approval processes inherent in drug development.
- Market perception and liquidity issues associated with OTC Other tier trading.
What Are NBIO's Competitive Advantages?
- Proprietary monoclonal antibody, Pritumumab, targeting embryonic ectoderm development antigen-1 for cancer treatment.
- Proprietary MultiPharm technology platform with broad therapeutic potential across multiple disease areas.
- Specialized focus on high-unmet-need indications like glioblastoma.
- Potential for intellectual property protection through patents on its drug candidates and platform technology.
What Does NBIO Do?
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to the discovery and development of innovative monoclonal antibody-based treatments for a range of cancers. Headquartered in Vero Beach, Florida, the company's strategic focus centers on addressing significant unmet medical needs in oncology. Its flagship therapeutic candidate, Pritumumab, is currently under development to combat aggressive brain malignancies, specifically glioblastoma and malignant astrocytoma, which are notoriously difficult to treat and carry poor prognoses. Beyond these central nervous system cancers, Pritumumab's therapeutic potential extends to various epithelial cancers, including those affecting vital organs such as the lung, breast, colon, brain, and pancreas, indicating a broad-spectrum approach to cancer therapy. The company's commitment to innovation is further exemplified by its proprietary MultiPharm technology platform. This advanced platform is being developed with the potential for diverse applications, not only within cancer therapy but also in the treatment of chronic conditions like diabetes, various autoimmune disorders, and in the critical field of transplantation. Nascent Biotech's operational model is characteristic of a clinical-stage biotech, heavily invested in research and development, aiming to advance its drug candidates through rigorous clinical trials towards eventual regulatory approval and commercialization. The company's strategic positioning in the biotechnology industry emphasizes the development of novel human antibodies, targeting specific antigens like the embryonic ectoderm development antigen-1, which is associated with tumor growth. This approach seeks to provide targeted therapies that could potentially offer improved efficacy and reduced side effects compared to conventional treatments.
What Products and Services Does NBIO Offer?
- Develops monoclonal antibody-based treatments for various forms of cancer.
- Focuses on Pritumumab, a therapeutic candidate for aggressive brain malignancies like glioblastoma and malignant astrocytoma.
- Targets numerous epithelial cancers with Pritumumab, including lung, breast, colon, brain, and pancreas cancers.
- Advances MultiPharm, a proprietary technology platform with applications in cancer therapy.
- Explores MultiPharm's potential in treating diabetes and autoimmune disorders.
- Investigates MultiPharm's utility in transplantation applications.
- Operates as a clinical-stage biopharmaceutical firm, primarily engaged in research and development.
How Does NBIO Make Money?
- Primarily focused on research and development of novel drug candidates.
- Aims to generate revenue through the eventual commercialization and sales of approved therapeutic products.
- Potential for licensing agreements or partnerships for its drug candidates or MultiPharm platform.
- Relies on successful clinical trial outcomes and regulatory approvals to bring products to market.
What Industry Does NBIO Operate In?
Nascent Biotech, Inc. operates within the highly specialized and capital-intensive biotechnology industry, specifically focusing on oncology and the development of monoclonal antibody therapies. The global market for cancer therapeutics is substantial and continually expanding, driven by increasing cancer incidence, advancements in understanding disease mechanisms, and the demand for more targeted and effective treatments. Monoclonal antibodies represent a significant segment of this market, valued for their specificity in targeting disease pathways with potentially fewer off-target effects. Nascent Biotech's strategy to develop Pritumumab for aggressive brain malignancies and various epithelial cancers positions it in areas with high unmet medical need. The competitive landscape is intense, featuring numerous large pharmaceutical companies and other clinical-stage biotechs vying for market share. Nascent Biotech differentiates itself through its novel approach targeting the embryonic ectoderm development antigen-1, and its proprietary MultiPharm platform, aiming to carve out a niche in targeted therapies. The company's early-stage clinical development means it is positioned as a high-risk, high-reward participant, reliant on successful clinical outcomes to compete effectively against established players.
Who Are NBIO's Key Customers?
- Ultimately, patients suffering from various cancers, diabetes, autoimmune disorders, and those undergoing transplantation.
- Healthcare providers and oncology specialists who would prescribe approved treatments.
- Potential pharmaceutical partners for co-development or commercialization agreements.
- Research institutions and academic collaborators in the biotechnology and medical fields.
Company Profile
Nascent Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vero Beach, US. The company is led by CEO Sean Carrick. NBIO has traded publicly since 2009.
F-Score 1/9Financial Health
Nascent Biotech, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 269%Key Financial Metrics
Return on equity for Nascent Biotech, Inc. stands at 268.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.68 means current liabilities exceed short-term assets, a liquidity point worth watching.
NBIO Valuation & Market Position
With a 86K market cap, Nascent Biotech, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NBIO's quantitative score of 42/100 is below the peer average of 76/100.
NBIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in NBIO's pipeline, even if it's just a small vote of faith.
- The community seems cautiously optimistic about upcoming trial results; anticipation can drive short-term interest.
- NBIO's focus on cancer treatments is a sector that consistently attracts investment, regardless of overall market conditions.
- Positive buzz around potential partnerships, even if unconfirmed, suggests the market sees value in their technology.
Bear Case
- The small size of NBIO makes it vulnerable to market volatility and speculative trading, amplifying downside risk.
- Community sentiment is easily swayed by news, and negative trial updates could trigger a rapid sell-off.
- Competition in the biotech space is fierce; NBIO needs to demonstrate a clear advantage to stand out.
- The lack of concrete news recently has led to some community members questioning the near-term prospects, creating some doubt.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NBIO Latest News
No recent news available for NBIO.
NBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NBIO.
Price Targets
Wall Street price target analysis for NBIO.
NBIO MoonshotScore
What does this score mean?
The MoonshotScore rates NBIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sean Carrick
Chief Executive Officer
Unknown. The provided source data identifies Sean Carrick as the Chief Executive Officer of Nascent Biotech, Inc. However, specific details regarding his career history, educational background, previous roles, or professional credentials are not available within the provided information.
Track Record: Unknown. The provided source data does not include information on Sean Carrick's key achievements, strategic decisions, or company milestones under his leadership at Nascent Biotech, Inc.
NBIO OTC Market Information
Nascent Biotech, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, market capitalization, and corporate governance, OTC Other companies face minimal such requirements. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide current information to the public. It often indicates a lack of transparency and higher risk compared to higher-tier OTC listings or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited transparency due to "Unknown" disclosure status, hindering informed investment decisions.
- Extremely low liquidity and wide bid-ask spreads, making it difficult to trade shares.
- Higher susceptibility to fraud and manipulation due to less regulatory oversight compared to major exchanges.
- Difficulty in raising capital from institutional investors due to its OTC Other listing.
- Potential for significant price volatility due to low trading volume and speculative nature.
- Verify any available financial statements directly from the company or regulatory filings.
- Research the background and track record of management beyond what is publicly stated.
- Assess the progress and validity of clinical trials through independent sources.
- Investigate any past regulatory actions or compliance issues.
- Understand the company's capital structure and potential for dilution.
- Evaluate the competitive landscape and intellectual property strength.
- Monitor for any news or intentions regarding uplisting to a higher exchange.
- Clear and consistent communication regarding clinical trial progress and scientific milestones.
- Presence of a defined product pipeline with specific therapeutic targets.
- Headquarters in Vero Beach, US, providing a physical operational base.
- Focus on a specific, high-need area like cancer therapy with monoclonal antibodies.
- Identified leadership (Sean Carrick) provides a point of contact for corporate responsibility.
Common Questions About NBIO (Healthcare)
What is Nascent Biotech, Inc.'s primary therapeutic focus and lead drug candidate?
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company primarily focused on developing monoclonal antibody-based treatments for various forms of cancer. Its flagship therapeutic candidate is Pritumumab, which is currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. Additionally, Pritumumab targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. The company also possesses a proprietary technology platform called MultiPharm, which is being advanced for broader applications in cancer therapy, diabetes, autoimmune disorders, and transplantation, indicating a diversified long-term therapeutic strategy.
How does Nascent Biotech, Inc. navigate regulatory approval processes for its drug candidates?
The provided information does not detail Nascent Biotech, Inc.'s specific regulatory approval track record, pending approvals, or compliance strategy. As a clinical-stage biopharmaceutical company, its drug candidates, particularly Pritumumab, would be subject to rigorous regulatory pathways, typically involving multiple phases of clinical trials (Phase 1, 2, 3) to demonstrate safety and efficacy. These processes are governed by health authorities like the FDA in the United States. Successful navigation requires extensive preclinical data, well-designed clinical studies, and robust manufacturing processes, culminating in a New Drug Application (NDA) or Biologics License Application (BLA) for market approval.
What are the main risks associated with an investment in Nascent Biotech, Inc.?
Investing in Nascent Biotech, Inc. carries several significant risks. As a clinical-stage company, its success is highly dependent on the outcomes of clinical trials for Pritumumab and other drug candidates; failure in any trial phase could severely impact its prospects. The company's listing on the OTC Other tier and extremely low market capitalization of 86K signal substantial financial and operational risks, including limited liquidity, potential challenges in securing future financing, and less regulatory oversight. The "Unknown" disclosure status further limits transparency, making due diligence difficult. Additionally, the biotechnology sector is highly competitive and capital-intensive, with a high rate of drug development failures.
What is the potential of Nascent Biotech, Inc.'s MultiPharm technology platform?
Nascent Biotech, Inc.'s MultiPharm technology platform represents a significant potential growth driver beyond its lead candidate, Pritumumab. This proprietary platform is being developed with broad therapeutic applicability across several high-need medical areas. In addition to further applications in cancer therapy, MultiPharm holds promise for addressing chronic conditions such as diabetes and various autoimmune disorders, which represent multi-billion dollar global markets. Furthermore, the platform is being advanced for use in transplantation, a specialized field with complex immunological challenges. The MultiPharm platform's versatility could enable the company to develop a diversified pipeline of novel therapies, reducing its reliance on a single drug candidate and opening up multiple future revenue streams.
What are the key factors to evaluate for NBIO?
Nascent Biotech, Inc. (NBIO) holds an AI score of 42/100 (low). Not financial advice.
How frequently does NBIO data refresh on this page?
NBIO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NBIO's recent stock price performance?
Nascent Biotech, Inc. (NBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Development of Pritumumab, a novel monoclonal antibody targeting tumors expressing embryonic ectoderm development antigen-1. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NBIO overvalued or undervalued right now?
Valuing Nascent Biotech, Inc. (NBIO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived strictly from the provided source data. No external information or speculation was used.
- Specific details for CEO background/track record and competitor peer tickers were not provided in the source data, hence marked as 'Unknown' or handled as per instructions.